Markt oder Branche auswählen:
Chart-Typ:
Zeitraum:
| Research and Markets: Europe Sodium-Ion Battery Analysis Report 2025: Market to Reach $1.49 Billion by 2035 from $50 Million in 2024, Driven by Sustainability, Energy Security, and Reduced Reliance on Imports - ResearchAndMarkets.com | The "Europe Sodium-Ion Battery Market: Focus on Application, Product, and Country Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets.com's offering.
The Europe sodium-ion... ► Artikel lesen |
| Dividendenbekanntmachungen (13.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABN AMRO BANK NV NL0011540547 - 0,54 EUR ADCORP HOLDINGS LIMITED ZAE000000139 0,5001 ZAR 0,0243 EUR AERCAP HOLDINGS NV NL0000687663 0... ► Artikel lesen |
| Reliance Industries to start solar cell production in India in Q3 | Reliance Industries Ltd. (RIL) is set to commission its solar cell factory in the third quarter, achieving a significant milestone in its goal of building a fully integrated solar manufacturing value... ► Artikel lesen |
| Tata verkündet Milliarden-Übernahme von Iveco | Tata Motors und die Iveco Group haben eine endgültige Vereinbarung geschlossen, welche die Übernahme des europäischen Nutzfahrzeugherstellers durch den indischen Autokonzern vorsieht. Erklärtes Ziel... ► Artikel lesen |
| Iveco Group N.V.: Tata Motors to Acquire Iveco Group | NOT FOR RELEASE, DISSEMINATION, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT... ► Artikel lesen |
| Dividendenbekanntmachungen (04.06.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADESSO SE DE000A0Z23Q5 - 0,75 EUR AGEAS SA/NV BE0974264930 - 2 EUR AIR LEASE CORPORATION US00912X3026 0,22 USD 0,1934 EUR ANALOG... ► Artikel lesen |
| Takeda Shares Promising Interim Results For Mezagitamab In IgA Nephropathy | TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) announced new interim findings from its Phase 1b open-label proof-of-concept trial evaluating subcutaneous mezagitamab (TAK-079)... ► Artikel lesen |
| Takeda Reports Positive Long-Term Data From Phase 3 Trial Of Dengue Vaccine QDENGA | TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) on Monday reported positive seven-year results from its pivotal Phase 3 TIDES trial evaluating the company's dengue vaccine, QDENGA... ► Artikel lesen |
| Takeda Pharma H1 Net Profit Declines; Revenue Down 6.9% | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) reported first half net profit to owners of company of 112.4 billion yen, down 40.0% from prior year. Earnings... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .